Related Experiment Video
Updated: Jan 1, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
ILC2s: New Actors in Tumor Immunity.
Giuseppe Ercolano1, Maryline Falquet1, Giulia Vanoni1
1Department of Oncology, Ludwig Institute for Cancer Research Lausanne, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Lausanne, Switzerland.
Group 2 innate lymphoid cells (ILC2s) are crucial for tissue health and immunity. Recent research highlights their emerging roles in cancer immunity and potential as targets for novel cancer immunotherapies.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Immunology
Background:
- Innate lymphoid cells (ILCs) are key immune sentinels for tissue homeostasis and barrier defense.
- Group 2 ILCs (ILC2s) are recognized regulators of allergic and asthmatic responses.
- The role of ILC2s in tumor immunity is an emerging area of investigation.
Purpose of the Study:
- To provide a comprehensive overview of the diverse functions of ILC2s in various cancer types.
- To explore the potential of targeting ILC2s to enhance existing cancer immunotherapies.
Main Methods:
- Literature review of ILC2 functions in different tumor microenvironments.
- Analysis of current therapeutic strategies involving ILC2 modulation.
- Synthesis of data on ILC2 involvement in tumor immunity.
Main Results:
- ILC2s exhibit multifaceted roles in different cancer settings, influencing anti-tumor and pro-tumor immunity.
- Modulating ILC2 activity presents a promising avenue for improving cancer immunotherapy efficacy.
- Understanding ILC2 plasticity is crucial for developing effective therapeutic interventions.
Conclusions:
- ILC2s are significant players in tumor immunity with both suppressive and stimulatory functions.
- Targeting ILC2s offers a novel strategy to augment current cancer treatments.
- Further research into ILC2 biology is warranted to optimize their therapeutic application in oncology.
More Related Videos
08:30Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
Published on: May 10, 2022
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...